WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016106359) COMBINATION OF RAF INHIBITORS AND TAXANES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/106359    International Application No.:    PCT/US2015/067462
Publication Date: 30.06.2016 International Filing Date: 22.12.2015
IPC:
A61K 31/505 (2006.01)
Applicants: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 40 Landsdowne Street Cambridge, MA 02139 (US)
Inventors: BOZON, Viviana; (US).
GALVIN, Katherine, M.; (US).
BRAKE, Rachael, L.; (US).
XU, Qunli; (US).
KANNAN, Karuppiah; (US)
Agent: STEFFE, Eric K.; (US)
Priority Data:
62/242,629 16.10.2015 US
62/096,020 23.12.2014 US
Title (EN) COMBINATION OF RAF INHIBITORS AND TAXANES
(FR) COMBINAISON D'INHIBITEURS DE RAF ET DE TAXANES
Abstract: front page image
(EN)The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.
(FR)La présente invention concerne des méthodes de traitement de cancers. En particulier, l'invention concerne des méthodes de traitement du cancer par administration d'un inhibiteur de Raf en combinaison avec un taxane. La présente invention concerne des méthodes de traitement d'un patient souffrant d'un cancer, comprenant l'administration au patient : (i) d'un inhibiteur de la Raf kinase ou d'un sel pharmaceutiquement acceptable associé ; et (ii) d'un taxane ou d'un sel pharmaceutiquement acceptable associé ; la quantité de l'inhibiteur de la Raf kinase et du taxane ou d'un sel pharmaceutiquement acceptable associé étant telle que la combinaison associée est thérapeutiquement efficace dans le traitement du cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)